Latest news for Oconomowoc Bancshares (OTC:OCNB) Stock

Oconomowoc Bancshares Inc operates as a bank holding company. It owns, operates, and controls one or more banks in the United States. Its services include savings accounts, deposits, loans, overdraft facilities, prepaid cards, eBanking, and telephone banking. The company provides services to corporations and individuals.

OCONOMOWOC BANCSHARES INC by Oconomowoc Bancshares, Inc.

Oconomowoc Bancshares Inc

EF Hutton analyst Jason Kolbert initiates coverage on CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy rating and announces Price Target of $10.

News

Price Target

Initiation

Analyst Ratings

CTSO

EF Hutton Initiates Coverage On CytoSorbents with Buy Rating, Announces Price Target of $10

The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Chesapeake Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHK#NASDAQ">CHK</a>)</h3>
<ul>
<li>On July 22, Truist Securities analyst Neal Dingmann maintained Chesapeake Energy with a Buy and lowered the price target from $112 to $108. The company's stock fell around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/CHK">52-week low of $72.84</a>.</li>
<li>RSI Value: 28.39</li>
<li>CHK Price Action: Shares of Chesapeake Energy gained 0.5% to close at $77.79 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">latest Chesapeake Energy news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="682" height="755" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033616/Screenshot-2024-07-29-at-1.06.10-PM.png" alt="" class="wp-image-461731" style="width:439px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033616/Screenshot-2024-07-29-at-1.06.10-PM.png 682w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033616/Screenshot-2024-07-29-at-1.06.10-PM-271x300.png 271w" sizes="(max-width: 682px) 100vw, 682px" /></a></figure>
<h3 class="wp-block-heading">EQT Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On July 23, EQT posted better-than-expected quarterly results. President and CEO Toby Z. Rice stated, &#8220;This week marked a significant milestone in the history of our company as we closed the acquisition of Equitrans, transforming EQT into America&#8217;s only large-scale, vertically integrated natural gas business. This combination creates a truly differentiated business model among the energy investment landscape, as EQT is now at the low end of the North American natural gas cost curve.&#8221; The company's stock fell around 5% over the past five days. It <a href="https://www.benzinga.com/quote/EQT">has a 52-week low</a> of $32.07.</li>
<li>RSI Value: 27.60</li>
<li>EQT Price Action: Shares of EQT fell 0.2% to close at $34.31 on Friday.</li>
<li><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">Benzinga Pro's charting tool</a> helped identify the trend in EQT stock.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="684" height="748" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033658/Screenshot-2024-07-29-at-1.06.53-PM.png" alt="" class="wp-image-461733" style="width:440px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033658/Screenshot-2024-07-29-at-1.06.53-PM.png 684w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033658/Screenshot-2024-07-29-at-1.06.53-PM-274x300.png 274w" sizes="(max-width: 684px) 100vw, 684px" /></a></figure>
<h3 class="wp-block-heading">Indonesia Energy Corp Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INDO#NYSE">INDO</a>)</h3>
<ul>
<li>On July 16, Indonesia Energy issued an operational update and said it has completed the recording of 29 square kilometers of new 3D seismic at its 63,000 acre Kruh Block. The company's stock dipped around 23% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/INDO">low of $2.03</a>.</li>
<li>RSI Value: 23.28</li>
<li>INDO Price Action: Shares of Indonesia Energy gained 1% to close at $2.12 on Friday.</li>
<li>Benzinga Pro's signals feature notified of a potential <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">breakout in Indonesia Energy shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="663" height="741" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033737/Screenshot-2024-07-29-at-1.07.33-PM.png" alt="" class="wp-image-461734" style="width:415px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033737/Screenshot-2024-07-29-at-1.07.33-PM.png 663w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033737/Screenshot-2024-07-29-at-1.07.33-PM-268x300.png 268w" sizes="(max-width: 663px) 100vw, 663px" /></a></figure>
<h3 class="wp-block-heading">BP Prudhoe Bay Royalty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BPT#NYSE">BPT</a>)</h3>
<ul>
<li>On July 5, BP Prudhoe Bay Royalty Trust said unitholders will not receive a dividend payment for the quarter ended June 30, 2024. The company's shares lost around 25% over the past five days. The company's 52-week low is $1.54.</li>
<li>RSI Value: 23.92</li>
<li>BPT Price Action: Shares of BP Prudhoe Bay Royalty Trust fell 5.2% to close at $1.63 on Friday.</li>
<li>Benzinga Pro's earnings calendar was used to track BPT <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">upcoming earnings report</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="742" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033838/Screenshot-2024-07-29-at-1.08.33-PM.png" alt="" class="wp-image-461736" style="width:397px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033838/Screenshot-2024-07-29-at-1.08.33-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/29033838/Screenshot-2024-07-29-at-1.08.33-PM-254x300.png 254w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">Jim Cramer Is &#8216;Mystified&#8217; By Five Below, Predicts CrowdStrike &#8216;Is Going To Bottom Here&#8217;</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

INDO

Top 4 Energy Stocks That May Rocket Higher In Q3

Baird analyst Ghansham Panjabi maintains Sensient Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXT#NYSE">SXT</a>) with a Outperform and raises the price target from $80 to $85.

Baird Maintains Outperform on Sensient Technologies, Raises Price Target to $85

CGTX

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

EF Hutton analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $46 price target.

AVXL

EF Hutton Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

Baird analyst David Leiker maintains Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) with a Outperform and lowers the price target from $40 to $38.

GNTX

Baird Maintains Outperform on Gentex, Lowers Price Target to $38

WIIM

BITF

CLSK

COIN

HIVE

MARA

MSTR

RIOT

Shares of crypto-linked stocks are trading higher as Bitcoin rises after Donald Trump advocated for a strategic national crypto stockpile.

$BTC

Bitcoin is trading higher after Donald Trump advocated for a strategic national crypto stockpile and said he would fire SEC Chair Gary Gensler.

Baird analyst Brian Skorney maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $316 to $294.

BIIB

Baird Maintains Outperform on Biogen, Lowers Price Target to $294

Stephens &amp; Co. analyst Russell Gunther maintains SouthState (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) with a Equal-Weight and raises the price target from $88 to $101.

Stephens & Co. Maintains Equal-Weight on SouthState, Raises Price Target to $101

Cannabis

General

TLRY

Tilray Brands Announced That Aphria RX Has Received A Trading License, Which Will Allow It To Sell And Distribute A Broad Range Of Medical Cannabis Products To Pharmacies, Hospitals, And Medical Wholesalers Throughout Germany

Baird analyst Catherine Schulte maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Outperform and raises the price target from $26 to $27.

AVTR

Baird Maintains Outperform on Avantor, Raises Price Target to $27

Stephens &amp; Co. analyst Russell Gunther maintains WSFS Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSFS#NASDAQ">WSFS</a>) with a Overweight and raises the price target from $54 to $62.

WSFS

Stephens & Co. Maintains Overweight on WSFS Financial, Raises Price Target to $62

IOVA

Iovance Biotherapeutics shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $19 to $10.

Stephens &amp; Co. analyst Andrew Terrell maintains First Interstate BancSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIBK#NASDAQ">FIBK</a>) with a Overweight and raises the price target from $32 to $36.

FIBK

Stephens & Co. Maintains Overweight on First Interstate BancSys, Raises Price Target to $36

Baird analyst Joel Beatty maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and raises the price target from $490 to $515.

ARGX

Baird Maintains Outperform on argenx, Raises Price Target to $515

The Dow Jones index closed higher by over 650 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ARCA biopharma</h3>
<ul>
<li>The Trade: ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 220,083 shares at</a> an average price of $3.18. To acquire these shares, it cost around $699,165.</li>
<li>What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.</li>
<li>What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.</li>
</ul>
<h3 class="wp-block-heading">Anixa Biosciences</h3>
<ul>
<li>The Trade: Anixa Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) Director Arnold M Baskies <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares at</a> an average price of $3.09. To acquire these shares, it cost around $15,450.</li>
<li>What's Happening: On July 23, Anixa Biosciences announced that its collaborator, Moffit Cancer Center, has received FDA approval for an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment.</li>
<li>What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology.</li>
</ul>
<h3 class="wp-block-heading">Lifeloc Technologies</h3>
<ul>
<li>The Trade: Lifeloc Technologies, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LCTC#OTC">LCTC</a>) CFO Vern D Kornelsen <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 45,620 shares</a> at an average price of $3.80. The insider spent around $173,356 to buy those shares. </li>
<li>What's Happening: On July 26, Lifeloc Technologies named Adam Kashenberg to its Board of Directors.</li>
<li>What Lifeloc Technologies Does: Lifeloc Technologies Inc is a developer, manufacturer, and marketer of portable hand-held and fixed station breathalyzers and related accessories, supplies and education.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/quote/CYAN/analyst-ratings">acquired a total of 10,000 shares </a>at an average price of $0.62. The insider spent around $6,200 to buy those shares.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984459/top-3-risk-off-stocks-that-are-set-to-fly-in-july">Top 3 Risk Off Stocks That Are Set To Fly In July</a></li>
</ul>

Penny Stocks

Insider Trades

ABIO

ANIX

CYAN

LCTC

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) had a challenging last week as bulls turned bearish after Elon Musk <a href="https://www.benzinga.com/news/24/07/39953071/tesla-ford-gm-and-other-automakers-trade-lower-in-premarket-after-elon-musk-and-jim-farleys-team-fai">failed to soothe investor worries</a> during the earnings call. However, a top Wall Street analyst has stood by the company&#8217;s stock price target, shifting the focus to the potential value of Tesla&#8217;s non-automotive divisions. 
What Happened: Tesla disclosed <a href="https://www.benzinga.com/news/earnings/24/07/39918390/tesla-q2-earnings-highlights-revenue-beat-eps-miss-robotaxi-update-2024-growth-rate-to-be-notably-l">weaker-than-expected Q2 earnings</a> and the lowest profit margins in half a decade, amid a worldwide EV price war and declining consumer demand. The company also postponed the launch of its highly anticipated robotaxi until October, or possibly later, due to last-minute design modifications.
Despite these hurdles, Morgan Stanley analyst Adam Jonas suggests that investors are excessively focused on the company&#8217;s automotive challenges, while underestimating the potential value of Tesla&#8217;s energy, AI, and robotics divisions. He contends that these sectors could offer greater shareholder value in the long run.
&#8220;While negative developments in the global EV market could impact the stock in the near-term, investors should not overlook Tesla's other plays, including recurring revenue from the Tesla fleet and areas like Energy Storage and Optimus,&#8221; Jonas said in a note.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-buy-tesla-stock" target="_blank" rel="noreferrer noopener">How To Buy Tesla Stock</a>
Jonas held his <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">$310 price target for Tesla</a>, underscoring that the company&#8217;s AI infrastructure assets are thriving, with shifts in the business mix being overlooked. He also spotlighted the company&#8217;s energy storage sector, which witnessed a record deployment of approximately 9.4 gigawatt hours of energy-storage products in the three months ending in June.
Jonas argues that the value and potential of these divisions now significantly surpass that of Tesla&#8217;s traditional carmaking unit. &#8220;Our thesis views Tesla as both an auto and an energy/AI/robotics company, with the core auto business valuation at $59/share, just ~19% of our $310 target.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Morgan Stanley&#39;s Adam Jonas: &quot;As <a href="https://twitter.com/Tesla?ref_src=twsrc%5Etfw">@Tesla</a> continues to diversify away from the auto industry and towards the autonomous industrial complex (AIC), we wanted to highlight some interesting information that, while they didn&#39;t grab any headlines, may be consequential over time.&quot; His… <a href="https://t.co/Mlp8TtX7IE">pic.twitter.com/Mlp8TtX7IE</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1816841828022251565?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h4 class="wp-block-heading">Tesla&#8217;s Future Beyond Cars</h4>
CEO Musk has also <a href="https://www.benzinga.com/news/24/07/39923738/tesla-reiterates-new-electric-vehicles-on-track-for-2025-but-ceo-elon-musk-refuses-to-divulge-detail">stressed the profit potential of AI technologies</a> and foresees a surge in capital spending to around $10 billion this year. Despite a 43% slump in earnings per share from last year, Tesla&#8217;s revenues managed to climb 3% to $25.5 billion, buoyed by stronger-than-expected delivery numbers.
Nonetheless, this did not result in higher profit margins, with Tesla&#8217;s gross margin of 14.6% being the lowest in at least five years. Musk has reiterated that full-year deliveries would be &#8220;meaningfully lower&#8221; than last year&#8217;s record tally of around 1.81 million but remains optimistic about the company&#8217;s future beyond carmaking.
<h4 class="wp-block-heading">What Other Analysts Are Saying?</h4>
The Future Fund LLC Managing Partner Gary Black criticized Tesla for its second-quarter earnings, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39953019/teslas-q2-earnings-lacked-in-analytical-rigor-and-strategic-direction-says-top-anal">citing a lack of analytical rigor</a> and a clear strategy. He highlighted the absence of analytical support for the company's market cap projections and called for a clearer strategy on margin stabilization, marketing, and the rollout of Full Self-Driving features. 
In his latest post, Black, who has significantly reduced his Tesla stake, discussed what would prompt him to increase his position. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40004926/tesla-investor-who-significantly-reduced-stake-ready-to-buy-back-in-heres-what-ev-m">He outlined three key points:</a> First, Tesla needs to stabilize and potentially boost auto gross margins by demonstrating a clear path to achieving this goal. Second, evidence of a return to 25%+ volume growth, driven by the launch of sub-$30K EVs, would expand the company's market. Finally, data showing that full self-driving technology can improve from 95%-96% to 99.99% efficacy could justify raising Tesla's price target to $270.
See Also: <a href="https://www.benzinga.com/money/how-to-invest-in-startups" target="_blank" rel="noreferrer noopener">How To Invest In Startups</a>
Stanphyl Capital's Mark Spiegel, a Tesla bear, noted that despite 55% of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39924771/bubble-fraud-tesla-worth-around-8-40-per-share-stock-valuation-under-scrutiny-as-ev">Tesla's operating income coming </a>from emission credit sales, the overall operating margin was only 6.3%. This is among the worst in the industry, he said. "This is bubble-fraud a car company that should sell at 4x earnings," he added.
However, just like Jonas, Jim Cramer <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39951197/jim-cramer-calls-elon-musk-bankable-and-visionary-as-tesla-shares-fall-over-12-why-">defended the electric vehicle maker</a> and its CEO Elon Musk. While Tesla missed the earnings estimates, Musk told a great story of self-driving technology, energy production, and humanoid robots, Cramer said. If not for the rotation out of big techs, Tesla would have been up in Wednesday's session, he said.
Price Action: Tesla closed Friday's session down 0.20% at $219.80, according to Benzinga Pro data, and has declined 11.52% year-to-date. However, during Monday&#8217;s premarket session, Tesla shares gained 0.80%, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39999031/elon-musks-optimism-doesnt-rub-off-on-investors-rivian-ceo-says-r2-not-model-y-copycat-gms-ev-go" target="_blank" rel="noreferrer noopener">Elon Musk's Optimism Doesn't Rub Off On Investors, Rivian CEO Says R2 Not Model Y Copycat, GM's EV Goals Scaled Back Yet Again And More: Biggest EV Stories Of The Week</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Equities

Tech

TSLA

As Tesla Stock Reels After A Rough Week Following Earnings, Top Analyst Defends Elon Musk's Ambitions For EV Giant Beyond Cars: 'Investors Should Not Overlook Tesla's Other Plays…'

Baird analyst Timothy Wojs maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Neutral and raises the price target from $132 to $160.

Baird Maintains Neutral on Mohawk Industries, Raises Price Target to $160

Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of A&beta;Os in AD patients. Soluble A&beta;Os are a highly toxic form of A&beta; that begin to accumulate before a clinical diagnosis of AD and are an early and persistent trigger of synaptic dysfunction and neurodegeneration. Acumen is developing sabirnetug as a potential next generation antibody treatment for early AD. The company is currently enrolling patients in the ALTITUDE-AD study, a Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of intravenous sabirnetug in patients with early AD.

Biotech

Health Care

ABOS

Acumen Pharmaceuticals Has Dosed The First Subject With A Subcutaneous Formulation Of Sabirnetug (ACU193) In A Phase 1 Pharmacokinetic Comparison Study To Compare Subcutaneous And Intravenous Administrations Of Sabirnetug In Healthy Volunteers

Oconomowoc Bancshares, Inc. goes ex dividend tomorrow

OCNB

Oconomowoc Bancshares

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Oconomowoc Bancshares

News

Latest news for Oconomowoc Bancshares (OTC:OCNB) Stock